Brand Name: Aricept, Aricept ODT
Generic Name: donepezil
Drug Class: Acetylcholinesterase Inhibitors, Central
What Is Donepezil and How Does It Work?
Donepezil is available under the following different brand names: Aricept, and Aricept ODT.
Dosages of Donepezil:
Dosage Forms and Strengths
- 5 mg
- 10 mg
- 23 mg
Tablet, oral disintegrating
- 5 mg
- 10 mg
Dosage Considerations – Should be Given as Follows:
Dementia of the Alzheimer's type
Mild to moderate
- 5 mg orally at bedtime initially, may increase to 10 mg/day after 4-6 weeks if warranted
Moderate to severe
- 5 mg orally at bedtime initially, may increase to 10 mg/day after 4-6 weeks; may further increase to 23 mg/day after 3 months if warranted
Take at bedtime before retiring
Take with or without food
- Treat for a minimum of 3 weeks and for at least 2 weeks following resolution of symptoms
- not studied
- not studied
Not recommended for pediatric use.
What Are Side Effects Associated with Using Donepezil?
Side effects associated with use of Donepezil, include the following:
- Loss of appetite
- High blood pressure (hypertension)
- Abnormal dreams
- Lightheadedness or fainting
Postmarketing side effects of donepezil reported include:
- Abdominal pain
- Heart block (all types)
- Hemolytic anemia
- Low blood sodium
- Muscle wasting (rhabdomyolysis)
- Neuroleptic malignant syndrome
- QTc prolongation
- Stevens Johnson syndrome
- Toxic epidermal necrolysis
- Torsade de pointes
This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.
What Other Drugs Interact with Donepezil ?
If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider or pharmacist first.
Severe interactions of donepezil include:
Serious interactions of donepezil include:
Donepezil has moderate interactions with at least 97 different drugs.
Donepezil has mild interactions with at least 156 different drugs.
This information does not contain all possible interactions or adverse effects. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns or for more information about this medicine.
What Are Warnings and Precautions for Donepezil ?
- This medication contains donepezil. Do not take Aricept or Aricept ODT if you are allergic to donepezil or any ingredients contained in this drug
- Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center immediately
- This medication contains donepezil
- Do not take Diflucan if you are allergic to donepezil or any ingredients contained in this drug
Effects of Drug Abuse
- No information provided
- See "What Are Side Effects Associated with Using Donepezil ?"
- See "What Are Side Effects Associated with Using Donepezil ?”
- Risk of GI bleed, especially in patients with history of gastric ulcer or those on nonsteroidal anti-inflammatory drugs (NSAIDs)
- Cholinesterase inhibitors are likely to exaggerate succinylcholine-type muscle relaxation during anesthesia
- Cholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes manifesting as bradycardia or heart block
- Can cause vomiting (higher risk with dose of 23 mg/day)
- May cause anorexia and/or weight loss (dose dependent)
- Cholinomimetics may cause bladder outflow obstructions
- Cholinomimetics are believed to have some potential to cause generalized convulsions
- Cholinesterase inhibitors should be prescribed with care with history of asthma or obstructive pulmonary disease
- Use with caution in patients with history of seizure disorders, urinary tract obstruction, peptic ulcer disease, cardiac conduction abnormalities, or respiratory disease including COPD or asthma
- May be associated with QT prolongation and torsades de pointes; use caution in patients at risk of cardiac repolarization
- Rare cases of neuroleptic malignant syndrome reported; may consider discontinuing therapy if symptoms occur
- Rare cases of rhabdomyolysis reported following few months of therapy or following therapy initiation; use caution in patients with risk factors rhabdomyolysis, including medications associated with rhabdomyolysis; consider discontinuing therapy if marked elevation of CPK levels or symptoms suggesting rhabdomyolysis occur
- Low weight patients under 55 kg may experience more weight loss, nausea, and vomiting than patients greater than 55 kg